Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Sabin Göktas Aydin"'
Autor:
Birol Ocak, Ahmet Bilgehan Sahin, Ismail Ertürk, Mustafa Korkmaz, Dilek Erdem, Umut Cakıroglu, Mustafa Karaca, Ahmet Dirican, Omer Fatih Olmez, Sabin Goktas Aydın, Ali Gökyer, Ahmet Kücükarda, Ahmet Gülmez, Perran Fulden Yumuk, Nazim Can Demircan, Abdilkerim Oyman, Teoman Sakalar, Fatih Karatas, Hacer Demir, Ayse Irem Yasin, Adem Deligonul, Bahar Dakiki, Mehmet Refik Goktug, Okan Avcı, Seher Yildiz Tacar, Nazım Serdar Turhal, Gülhan Ipek Deniz, Turgut Kacan, Erdem Cubukcu, Türkkan Evrensel
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5195-5205 (2024)
Background: This study aimed to investigate the effect of cytoreductive nephrectomy (CN) on the survival outcomes of nivolumab used as a subsequent therapy after the failure of at least one anti-vascular endothelial growth factor (VEGF) agent in pati
Externí odkaz:
https://doaj.org/article/e3b91b5047204acf948136cd657f8dec
Autor:
Ayse Irem Yasin, Sabin Göktas Aydin, Bilge Sümbül, Lokman Koral, Melih Şimşek, Çağlayan Geredeli, Akın Öztürk, Perihan Perkin, Derya Demirtaş, Engin Erdemoglu, İlhan Hacıbekiroglu, Emre Çakır, Eda Tanrıkulu, Ezgi Çoban, Melike Ozcelik, Sinemis Çelik, Fatih Teker, Asude Aksoy, Sedat T Fırat, Ömer Tekin, Ziya Kalkan, Orhan Türken, Bala B Oven, Faysal Dane, Ahmet Bilici, Abdurrahman Isıkdogan, Mesut Seker, Hacı M Türk, Mahmut Gümüş
Publikováno v:
Future Oncology
Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce80e141c2165fb933786d2089960e2a
https://hdl.handle.net/11424/286170
https://hdl.handle.net/11424/286170
Autor:
Sabin Goktas Aydin, Engin Eren Kavak, Atakan Topcu, Ayberk Bayramgil, Fahri Akgul, Seda Kahraman, Musa Baris Aykan, Yunus Emre Altıntas, Kaan Helvaci, Yuksel Urun, Ahmet Bilici, Mesut Seker, Mehmet Ali Nahit Sendur, Omer Fatih Olmez, Ozgur Acikgoz, Irfan Cicin
Publikováno v:
Biomolecules & Biomedicine, Vol 23, Iss 6 (2023)
Regorafenib, an oral multikinase inhibitor, has improved survival in metastatic colorectal cancer (mCRC) patients who have progressed on standard therapies. Our study aimed to evaluate prognostic factors influencing regorafenib treatment and assess t
Externí odkaz:
https://doaj.org/article/307cb5703f46446fb0e16815e2f38f8b